Akeso Unveils Promising Data on Ivonescimab at ESMO 2026, Strengthening Its Oncology Portfolio #Hong_Kong #Akeso #Ivonescimab #ESMO
@newsen.bsky.social
@newsen.bsky.socialAkeso Unveils Promising Data on Ivonescimab at ESMO 2026, Strengthening Its Oncology Portfolio #Hong_Kong #Akeso #Ivonescimab #ESMO
@newsen.bsky.socialPromising Survival Results for Ivonescimab Over Pembrolizumab in NSCLC Treatment at WCLC 2026 #None #Hong_Kong #Akeso #Ivonescimab #Pembrolizumab
@newsen.bsky.socialSignificant Survival Advantage of Ivonescimab Over Pembrolizumab in NSCLC: HARMONi-2 Study Insights #None #Akeso #Ivonescimab #Pembrolizumab
@pharmaphorum.bsky.social#Akeso and #Summit's PD-1xVEGF drug #ivonescimab has improved overall survival in another phase 3 trial, this time when used as a first-line treatment for PD-L1-positive non-small cell lung cancer (#NSCLC).